TLE3 as a candidate biomarker of response to taxane therapy. - Wikidata - awgldk - TriplyDB

TLE3 as a candidate biomarker of response to taxane therapy.

TLE3 as a candidate biomarker of response to taxane therapy.

http://www.wikidata.org/entity/Q37208764

about

Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.TLE4 promotes colorectal cancer progression through activation of JNK/c-Jun signaling pathway Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.TLE3 represses colorectal cancer proliferation by inhibiting MAPK and AKT signaling pathways.Molecular profiling of head and neck squamous cell carcinoma.Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.Transducin-Like Enhancer of Split 3 (TLE3) expression is associated with taxane sensitivity in non-serous ovarian carcinoma in a three-cohort study.β3-tubulin is a good predictor of sensitivity to taxane-based neoadjuvant chemotherapy in primary breast cancer.Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness.

P2860

Q34375087-B93221AB-EA7C-4141-829F-57E119591507 Q34555411-5CA6FFC5-2AD9-4F47-ADA9-F4B766CD5CED Q36027073-D0527807-E97B-4D87-82C0-6C3A8D031C8E Q36771972-C5EDAC71-6448-4A3E-A5F0-D5FBDF06A6BD Q37116937-FB75BC5E-B3F3-4266-8EE0-432787EF6239 Q37286140-E370B952-23CD-461A-81D1-1045D74D8533 Q37337359-477C3CE2-E3FC-4A1B-8A24-155102C9BFA3 Q38272730-51D23E25-DCBA-4787-9884-7F04A60FD7DE Q41588399-B7BB7B6D-EAD1-4980-9F2B-CB9AC3EB95C6 Q52727051-A3C96448-8248-425C-A4CA-219953646054 Q53837284-BE30A3D8-A9A1-48C4-9C64-70BBDE184CC1 Q55055140-821F7AEA-9309-4096-B133-DA621932A82C

P2860

TLE3 as a candidate biomarker of response to taxane therapy.

http://www.wikidata.org/entity/Q37208764

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

TLE3 as a candidate biomarker of response to taxane therapy.

@en

TLE3 as a candidate biomarker of response to taxane therapy.

@nl

type

label

TLE3 as a candidate biomarker of response to taxane therapy.

@en

TLE3 as a candidate biomarker of response to taxane therapy.

@nl

prefLabel

TLE3 as a candidate biomarker of response to taxane therapy.

@en

TLE3 as a candidate biomarker of response to taxane therapy.

@nl

P1433

Q37208764-B9919D6F-2C02-413A-9209-FA7C06758F93

P1476

Q37208764-0A78D855-87FC-42B0-A300-B0541231929B

P2093

Q37208764-1404A3D7-60AA-448B-B030-779B2E48A4B2

Q37208764-3419B920-2C76-431E-A43B-13F21B8B0056

Q37208764-42D6DF06-DA24-459D-B84D-07FBB7CABBAE

Q37208764-45BE3305-3A95-4F65-9D78-CFAD86F2E418

Q37208764-5F94C9C2-90B4-4AC7-B8CF-E6924773E29C

Q37208764-99A28DAB-0C8F-40F6-8353-28D737B9EBF3

Q37208764-A0C748E6-FB8F-4231-8210-769ECD68C4A1

Q37208764-B608945D-EA3B-4B83-817A-C9B3662DB112

Q37208764-D2E2E95A-E30F-408C-B197-D4DC40FAC194

Q37208764-ED9B5DCD-0DC9-45AB-8EC6-72F4CCE89242

P2860

Q37208764-072CB4D7-9207-460A-A2DE-1C3AC4A8883E

Q37208764-076292DB-475B-46D5-8BE0-A8C7DE722F44

Q37208764-1C7C9EE6-36F5-4EB2-B158-2F5C6C577368

Q37208764-284956F9-ABAF-4BD1-BB2E-2DFF35502960

Q37208764-2DBAD123-053C-4D35-852A-905512E0F637

Q37208764-3E19377E-3B06-4DE7-845A-7AC2B735BEDD

Q37208764-45EC4E50-C4B3-489C-901F-470BDD67D0FD

Q37208764-5107D148-2B1C-403D-A086-1DCFA5C84B49

Q37208764-510E2C96-5228-472D-A7F1-AD6FA53D1033

Q37208764-54EB2F7B-16DB-42C3-9857-8EAB4259AB68

P2888

Q37208764-E8FB3B24-6845-4386-A9C5-D24A5FB56518

P304

Q37208764-E0DA5CA7-7D23-458F-BB6E-14C68062FE1F

P31

Q37208764-D2548AB3-DC2D-4CEE-BA65-44ACEEA2B3A2

P356

Q37208764-06594357-7CBA-4642-99D5-F8712CBC3F76

P433

Q37208764-FD4C8424-4D02-431F-9FF8-A2CFAA066733

P478

Q37208764-EE0518DF-7D0F-472B-A24B-51E1D2603C3F

P50

Q37208764-9F1BDC11-AE93-4FF6-8ADD-48761B9A548C

P577

Q37208764-1F0CF5C2-27A7-439D-A0CF-9D558396E11E

P5875

Q37208764-8E81DA30-B667-4008-AFA1-6BF1B666A9B6

P6179

Q37208764-F1EA15A5-E4CE-4953-AB7D-2FBC3C2DD1EF

P698

Q37208764-8D83F0D7-FFEE-4D7B-8957-A09B64839559

P921

Q37208764-F4C68AEB-D342-41B0-976B-7F7BF1D1659E

P932

Q37208764-91634C11-3E6F-4028-A06A-160F2553A267

P356

P1433

Breast Cancer Research

P1476

TLE3 as a candidate biomarker of response to taxane therapy.

@en

P2093

Brian Z Ring

http://www.w3.org/2001/XMLSchema#string

Christine Murekeyisoni

http://www.w3.org/2001/XMLSchema#string

David G Hicks

http://www.w3.org/2001/XMLSchema#string

Helena Hwang

http://www.w3.org/2001/XMLSchema#string

Marshall T Schreeder

http://www.w3.org/2001/XMLSchema#string

Nancy L Watroba

http://www.w3.org/2001/XMLSchema#string

Noel C Estopinal

http://www.w3.org/2001/XMLSchema#string

Robert S Seitz

http://www.w3.org/2001/XMLSchema#string

Rodney A Beck

http://www.w3.org/2001/XMLSchema#string

Swati A Kulkarni

http://www.w3.org/2001/XMLSchema#string

P2860

Epithelial expression and chromosomal location of human TLE genes: implications for notch signaling and neoplasia

Repression by Groucho/TLE/Grg proteins: genomic site recruitment generates compacted chromatin in vitro and impairs activator binding in vivo

Repeated observation of breast tumor subtypes in independent gene expression data sets

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

Groucho/TLE family proteins and transcriptional repression

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Identification of genes periodically expressed in the human cell cycle and their expression in tumors

Paclitaxel (taxol)

Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.

P2888

P304

R17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2241

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Douglas T. Ross

P577

2009-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24222693

http://www.w3.org/2001/XMLSchema#string

P6179

1037061114

http://www.w3.org/2001/XMLSchema#string

P698

19309506

http://www.w3.org/2001/XMLSchema#string

P921

P932

2688945

http://www.w3.org/2001/XMLSchema#string